SCHEMBL15064987

SCHEMBL15064987

CNC(=O)Nc1cccc(Br)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.62
TGM2 P21980 1/20 0.57
ALDH1A1 P00352 3/20 0.54
RAB9A P51151 2/20 0.54
HPGD P15428 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
P2RX1 P51575 1/20 0.53
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
KDM4E B2RXH2 1/20 0.51
NPC1 O15118 1/20 0.51
LMNA P02545 1/20 0.51
ALOX15 P16050 1/20 0.51
TRPV1 Q8NER1 1/20 0.51
STING1 Q86WV6 1/20 0.51
GRIK1 P39086 1/20 0.51
GRIK2 Q13002 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
POLB P06746 1/20 0.51
MAPT P10636 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19707566 0.88 GAA (0.65) GAATGM2ALDH1A1RAB9AP2RX1
SCHEMBL29556097 0.83 MAOA (0.69) GAATGM2ALDH1A1RAB9AHPGD
SCHEMBL29556941 0.83 GAA (0.59) GAATGM2ALDH1A1RAB9AP2RX1
SCHEMBL11051606 0.81 MAOA (0.72) GAATGM2ALDH1A1RAB9ASMN1; SMN2
SCHEMBL7514364 0.81 IDO1 (0.64) GAATGM2ALDH1A1RAB9AHPGD
SCHEMBL264735 0.81 GAA (0.66) GAATGM2ALDH1A1RAB9AHPGD
SCHEMBL16488795 0.81 MEN1 (0.51) ALDH1A1SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL11003357 0.81 POLB (0.60) GAATGM2ALDH1A1RAB9ASMN1; SMN2
SCHEMBL11908700 0.81 GAA (0.66) GAATGM2ALDH1A1RAB9AHPGD
SCHEMBL21928147 0.81 RAB9A (0.65) GAATGM2ALDH1A1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3643308-B1 COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF CSTONE PHARMACEUTICALS (KY) 2021-05-19 EP disclosed
EP-3643308-A1 COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF CSTONE PHARMACEUTICALS (KY) 2020-04-29 EP disclosed
EP-3381995-B1 OIL-GELLING AGENT UNIV SHIZUOKA NAT UNIV CORP (JP) 2019-10-23 EP disclosed
US-10351522-B2 Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof UNIVERSITY OF TSUKUBA (JP) 2019-07-16 US disclosed
US-20180179151-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF UNIVERSITY OF TSUKUBA (JP) 2018-06-28 US disclosed
EP-3309146-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF University of Tsukuba (JP) 2018-04-18 EP disclosed
US-20130172384-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED 2013-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180179151-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF HCRTR2, HCRTR1, NPSR1 GAA 925/4885TGM2 3465/4885ALDH1A1 968/4885
US-10351522-B2 Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof HCRTR2, HCRTR1, NPSR1 GAA 925/4885TGM2 3465/4885ALDH1A1 968/4885
US-20130172384-A1 FATTY ACID SYNTHASE INHIBITORS FASN, FADS1, FADS2 GAA 1730/4885TGM2 842/4885ALDH1A1 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.